Aiosyn
The rapid evolution of AI in healthcare presents a unique opportunity to transform pathology. By automating complex diagnostic tasks, Aiosyn’s AI solutions empower pathologists to deliver faster, more consistent results and ultimately improving outcomes for cancer patients. Aiosyn’s algorithms are designed to enhance both the speed and precision of pathology workflows. This helps to reduce healthcare costs and deliver more actionable insights for clinicians.
Partnership with TNO
The strategic partnership between Aiosyn and TNO creates powerful synergies: Aiosyn will benefit from TNO’s world-class research facilities and network to accelerate the clinical validation and market readiness of its AI software, while TNO gains access to Aiosyn’s cutting-edge AI expertise to strengthen and innovate its leading position in preclinical contract research services. This collaboration reflects TNO’s evolving role as a strategic investor in key technologies that strengthen both its research capabilities and the Dutch tech ecosystem.
“Aiosyn exemplifies the kind of bold, forward-thinking innovation that TNO is proud to support, delivering on TNO’s strategy to help Dutch tech companies scale globally and lead in key technologies”, said Hans Boumans, Director of TNO Ventures.
Tech participations
TNO makes its technologies, expertise and facilities available to companies through licensing agreements and Tech Participations. Startups and scaleups pay for this in shares, thereby reducing cash-outs. In turn, TNO becomes a strategic partner that helps with the growth and development of innovative enterprises.
TNO Ventures' involvement in spin-offs, startups and scaleups is temporary. Once the companies have grown sufficiently, TNO seeks a suitable exit.
Want to know more about Tech Participations?